Takeaways: Health Canada’s approval of Fasenra for hypereosinophilic syndrome (HES) gives Canadian patients a much‑needed, evidence‑backed option that can cut flare‑ups and improve fatigue, potentiall...
Takeaways The Canadian NOC formally moves Scenesse from special‑access cases to on‑label, publicly or privately reimbursed treatment for erythropoietic protoporphyria, e...
